Pedro Such

Valby, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Safety and Efficacy of Maintenance Treatment With Aripiprazole Once-Monthly in Black/African American Adults Diagnosed With Bipolar I Disorder: Post Hoc Analysis of a 52-Week, Open-Label Study.

Safety and Efficacy of Maintenance Treatment With Aripiprazole Once-Monthly in Black/African American Adults Diagnosed With Bipolar I Disorder: Post Hoc Analysis of a 52-Week, Open-Label Study.

Journal: The Journal of clinical psychiatry

Published: April 07, 2026

Brexpiprazole for treating agitation in different groups of people with Alzheimer's dementia: a plain language summary.

Brexpiprazole for treating agitation in different groups of people with Alzheimer's dementia: a plain language summary.

Journal: Neurodegenerative disease management

Published: February 14, 2026

Brexpiprazole side-effect profile in people with agitation in Alzheimer's dementia: a plain language summary.

Brexpiprazole side-effect profile in people with agitation in Alzheimer's dementia: a plain language summary.

Journal: Current medical research and opinion

Published: January 14, 2026

Efficacy of Brexpiprazole on Neuropsychiatric Symptoms and Impact on Caregivers: Pooled Neuropsychiatric Inventory (NPI) Analysis in Patients With Agitation Associated With Dementia due to Alzheimer's Disease.

Efficacy of Brexpiprazole on Neuropsychiatric Symptoms and Impact on Caregivers: Pooled Neuropsychiatric Inventory (NPI) Analysis in Patients With Agitation Associated With Dementia due to Alzheimer's Disease.

Journal: Journal of geriatric psychiatry and neurology

Published: December 24, 2025

Brexpiprazole for Agitation in Patients with Alzheimer's Dementia with and without Co-Occurring Psychosis: Post Hoc Analysis of Short- and Long-Term Trials.

Brexpiprazole for Agitation in Patients with Alzheimer's Dementia with and without Co-Occurring Psychosis: Post Hoc Analysis of Short- and Long-Term Trials.

Journal: Neuropsychiatric disease and treatment

Published: December 05, 2025

Understanding patient, caregiver, and prescriber preferences for an antipsychotic regimen administered once every 2 months for schizophrenia or bipolar I disorder: a qualitative interview study in North America.

Understanding patient, caregiver, and prescriber preferences for an antipsychotic regimen administered once every 2 months for schizophrenia or bipolar I disorder: a qualitative interview study in North America.

Journal: Current medical research and opinion

Published: November 21, 2025

Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer's Disease: Timing and Duration of Adverse Events.

Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer's Disease: Timing and Duration of Adverse Events.

Journal: Drug safety

Published: September 08, 2025

Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease.

Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer's disease.

Journal: Current medical research and opinion

Published: August 23, 2025

Views on an antipsychotic regimen administered once every 2 months: a qualitative interview study of people living with bipolar I disorder, caregivers, and prescribers in the USA and Canada.

Views on an antipsychotic regimen administered once every 2 months: a qualitative interview study of people living with bipolar I disorder, caregivers, and prescribers in the USA and Canada.

Journal: International journal of bipolar disorders

Published: June 08, 2025

Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial.

Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer's Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial.

Journal: CNS drugs

Published: June 05, 2025

Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer's Disease: Pooled Analysis of Randomized Controlled Trials.

Efficacy of Brexpiprazole in Participants with Agitation Associated with Dementia Due to Alzheimer's Disease: Pooled Analysis of Randomized Controlled Trials.

Journal: Clinical drug investigation

Published: May 14, 2025

Exposure-Response Analysis for Aripiprazole Once-Monthly in Patients Diagnosed With Bipolar I Disorder.

Exposure-Response Analysis for Aripiprazole Once-Monthly in Patients Diagnosed With Bipolar I Disorder.

Journal: Clinical pharmacology in drug development

Published: March 07, 2025

Showing 1-12 of 36

Last Updated: 09/26/2026